Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System

Ann Rheum Dis. 2021 Dec;80(12):1633-1635. doi: 10.1136/annrheumdis-2021-220679. Epub 2021 Jul 20.
No abstract available

Keywords: COVID-19; autoimmune diseases; biological therapy; therapeutics.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Adverse Drug Reaction Reporting Systems
  • Aged
  • Aged, 80 and over
  • Autoimmune Diseases / drug therapy*
  • COVID-19 / immunology
  • COVID-19 / mortality*
  • Child
  • Child, Preschool
  • Drug-Related Side Effects and Adverse Reactions / mortality*
  • Female
  • Humans
  • Immunotherapy / adverse effects*
  • Male
  • Middle Aged
  • SARS-CoV-2*
  • United States
  • United States Food and Drug Administration
  • Young Adult